Accrual of radiotherapy patients to clinical trials
نویسندگان
چکیده
منابع مشابه
Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials.
PURPOSE The need to increase the number oncology clinical trials with sufficient enrollments is a well-known issue, particularly for trials targeting therapeutic applications. It is critical to identify early predictors of eventual study accrual achievement. EXPERIMENTAL DESIGN All nonpediatric phase I, I/II, II, and III therapeutic studies supported by the National Cancer Institute Cancer Th...
متن کاملPredicting accrual in clinical trials with Bayesian posterior predictive distributions.
Investigators need good statistical tools for the initial planning and for the ongoing monitoring of clinical trials. In particular, they need to carefully consider the accrual rate-how rapidly patients are being recruited into the clinical trial. A slow accrual decreases the likelihood that the research will provide results at the end of the trial with sufficient precision (or power) to make m...
متن کاملEvaluation of Clinical Trials
In a number of important clinical issues such as evaluation of the efficacy or effectiveness of therapeutic or preventive interventions as well as for comparing the harms of interventions, randomized controlled trials (RCTs) provide the highest levels of evidence, either directly or indirectly. It is obvious that critical appraisal of these studies to assess their validity and precision is of p...
متن کاملAccrual monitoring in cardiovascular trials
Objective To provide brief guidance on how to design accrual monitoring activities in a clinical trial protocol. Setting Two completed clinical trials that did not achieve the planned sample size, the Cost of Strategies After Myocardial Infarction (COSTAMI) trial and the Biventricular Pacing After Cardiac Surgery (BiPACS) trial. Design A Bayesian monitoring tool, the constant accrual model,...
متن کاملAccrual to cancer clinical trials in the era of molecular medicine.
Enrollment of patients in a clinical trial is difficult as a result of a host of well-documented barriers. In the field of oncology, molecularly targeted treatments have demonstrated considerable therapeutic promise. At the same time, clinical testing of these targeted agents has introduced new complexities in the decision-making process by patients or providers on whether to participate in cli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1983
ISSN: 0008-543X,1097-0142
DOI: 10.1002/1097-0142(19830915)52:6<1014::aid-cncr2820520614>3.0.co;2-j